drugset / Trial / NCT01720576

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)

NCT01720576

Phase 1 Completed 60 enrolled Regeneron Pharmaceuticals Sanofi · collab
RandomizedSingle-groupQuadruple-blindTreatment

Summary

This is a study to assess the safety and tolerability of subcutaneously administered REGN1033 (SAR391786) in healthy volunteers.

Timeline

Start
2012-10
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Trevogrumab Monoclonal antibody Subcutaneous

Indications

No indication recorded.